Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-09-25
2007-09-25
Saunders, David A. (Department: 1644)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007210, C435S029000, C435S377000
Reexamination Certificate
active
10026335
ABSTRACT:
The present invention relates to compositions and methods for identification and development of compounds or therapeutic agents that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to methods for detecting compounds or therapeutic agents that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in cells. The present invention provides compositions for and methods of treatment of biological conditions including, but not limited to, vascular complications of type I and type II diabetic induced vasculopathies, other vasculopathies, microangiopathies, renal insufficiency, Alzheimer's syndrome, and inflammation-induced diseases such as atherosclerosis.
REFERENCES:
patent: 5846959 (1998-12-01), Medford et al.
patent: 6340459 (2002-01-01), Yellin et al.
patent: 6900041 (2005-05-01), Cahoon et al.
patent: 7173032 (2007-02-01), Timmer et al.
patent: 2002/0086282 (2002-07-01), Pillarisetti et al.
patent: WO97/20063 (1997-06-01), None
Cruse et al, Illustrated Dictionary of Immunology, CRC Press, 1995, pp. 302-303.
Brownlee, M., et al., “Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking”,Science, vol. 232, pp. 1629-1632, (1986).
Brownlee, M., et al., “Nonenzymatic glycosylation and the pathogenesis of diabetic complications”,Annuals of Internal Medicine, vol. 101, pp. 527-537, (1984).
Cohen, M.P., et al., “Role of amadori-modified nonenzymatically glycated serum proteins in the pathogenesis of diabetic nephropathy”,Journal of the American Society of Nephrology, vol. 7, No. 2, pp. 183-190.
Eitner, F., et al., “Role of interleukin-6 in mediating mesangial cell proliferation and matrix productionin vivo”, Kidney International, vol. 51, pp. 69-78 (1997).
Hofmann, M. A., et al., “RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/Calgranulin polypeptides”,Cell, vol. 97, pp. 889-901 (1999).
Horii, Y., et al., “Role of interleukin-6 in the progression of mesangial proliferative glomerulonephritis”,Kidney International, vol. 43, Suppl. 39, pp. S-71-S-75, (1993).
Huber, S.A., et al., “Interleukin-6 exacerbates early atherosclerosis in mice”,Arterioscler. Thromb. Vasc. Biol., vol. 19, pp. 2364-2367.
Kado, S., et al., “Circulating levels of interleukin-6, its soluble receptor and interleukin-6/interleukin-6 receptor complexes in patients with type 2 diabetes mellitus”,Acta. Diabetol., vol. 36, pp. 67-72, (1999).
Lander, H. M., et al., “Activation of the receptor for advanced glycation end products triggers a p21ras-dependent mitogen-activated protein kinase pathway regulated by oxidant stress”,The Journal of Biological Chemistry, vol. 272, No. 28, pp. 17810-17814 (1997).
Li, Y.M., et al., “Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine”,Proc. Natl. Acad. Sci., vol. 93, pp. 3902-3907 (1996).
Morohoshi, M., et al., “The effect of glucose and advanced glycosylation end products on IL-6 production by human monocytes”,Annals of the New York Academy of Sciences, vol. 748, pp. 562-570 (1995).
Park, L., et al., “Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts”,Nature Medicine, vol. 4, No. 9, pp. 1025-1031 (1998).
Piercy, V., et al., “Potential benefit of inhibitors of advanced glycation end products in the progression of type II diabetes: A study with aminoguanidine in C57/BLKsJ diabetic mice”,Metabolism, vol. 47, No. 12, pp. 1477-1480 (1998).
Saitoh A., et al., “Urinary levels of monocyte chemoattractant protein (MCP)-1 and disease activity in patients with IgA nephropathy”,Journal of Clinical Laboratory Analysis, vol. 12, pp. 1-5, (1998).
Schmidt, A.M., et al., “Activation of receptor for advanced glycation end products”,Circulation Research, vol. 84, pp. 489-497 (1999).
Schmidt, A.M., et al., “Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice”,Journal of Clinical Investigation, vol. 96, pp. 1395-1403 (1995).
Soulis, T., et al., “Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment”,Kidney International, vol. 50, pp. 627-634 (1996).
Taguchi, A., et al., “Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases”,Nature, vol. 405, pp. 354-360 (2000).
Takagi, M., et al., “Advanced glycation end products stimulate interleukin-6 production by human bone-derived cells”,Journal of Bone and Mineral Research, vol. 12, No. 3, pp. 439-446 (1997).
Thornalley, Paul J., “Cell activation by glycated proteins AGE receptors, receptor recognition factors and functional classifcation of AGEs”,Cellular and Molecular Biology, vol. 44., No. 7, pp. 1013-1023 (1998).
Wada, R., et al., “Only limited effects of aminoguanidine treatment on peripheral nerve function, (Na+, K+)-ATPase activity and thrombomodulin expression in streptozotocin-induced diabetic rats”,Diabetologia, vol. 42, pp. 743-747 (1999).
Wautier, J.L., et al., “Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy”,J. Clin. Invest., vol. 97, No. 1, pp. 238-243 (1996).
Yan, S., et al., “Amyloid-beta peptide-receptor for advanced glycation end product interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease.”Proc. Natl. Acad. Sci. U.S.A., vol. 94, pp. 5296-5301 (1997).
Yang, C.W., et al., “Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease.,”Proc. Natl. Acad. Sci. U. S. A., vol. 91, pp. 9436-9440 (1994).
Yano M, et al., “Immunohistochemical localization of glycated protein in diabetic rat kidney”Diabetes Res. and Clin. Pract., vol. 8, pp. 215-219 (1990).
Bian, Z.M., et al., “Glycated Human Serum Albumin Induces IL-8- and MCP-1 Gene Expression in Human Corneal Keratocytes”,Current Eye Research, vol. 17, pp. 65-72 (1998).
Sengoelge, G., et al., “Endothelial Cell Adhesion Molecule and PMNL Response to Inflammatory Stimuli and AGE-modified Fibronectin”,Kidney International, vol. 54, No. 5, pp. 1637-1651 (1998).
Schmidt, A.M., et al., “Activation of Receptor for Advanced Glycation End Products”,Circulation Research, vol. 84, pp. 489-497 (1999).
Marui, N. et al., Vascular Cell Adhesion Molecule-1 (VCAM-1) Gene Transcription and Expression are Regulated through an Antioxidant-sensitive Mechanism in Human Vascular Endothelial Cells, The American Society for Clinical Investigation, Inc., Oct. 1993, vol. 92, 1866-1874.
Schreck, R. et al., Dithiocarbamates as Potent Inhibitors of Nuclear Factor kB Activation in Intact Cells, J. Exp. Med., The Rockefeller University Press, May 1992, vol. 175, 1181-1194.
Neumann, A. et al., Pro-Inflammatory Effects of AGEs: AGE-Induced Transduction in Macrophages, Journal of the American Society of Nephrology, Sep. 2000, 485A, vol. 11, American Society of Nephrology, U.S.A.
Cahoon Shianlen
Pillarisetti Sivaram
Saxena Uday
Reddy US Therapeutics Inc.
Saunders David A.
Thomas Robert S.
LandOfFree
Methods and compositions for detecting compounds that... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for detecting compounds that..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for detecting compounds that... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3731228